[go: up one dir, main page]

WO2005097831A3 - Uses of isolated binding members capable of binding specifically to secretagogues - Google Patents

Uses of isolated binding members capable of binding specifically to secretagogues Download PDF

Info

Publication number
WO2005097831A3
WO2005097831A3 PCT/DK2005/000241 DK2005000241W WO2005097831A3 WO 2005097831 A3 WO2005097831 A3 WO 2005097831A3 DK 2005000241 W DK2005000241 W DK 2005000241W WO 2005097831 A3 WO2005097831 A3 WO 2005097831A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
binding members
individual
isolated
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2005/000241
Other languages
French (fr)
Other versions
WO2005097831A2 (en
Inventor
Christian Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gastrotech Pharma AS
Original Assignee
Gastrotech Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastrotech Pharma AS filed Critical Gastrotech Pharma AS
Publication of WO2005097831A2 publication Critical patent/WO2005097831A2/en
Publication of WO2005097831A3 publication Critical patent/WO2005097831A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising isolated binding members, such as antibodies and/or affibodies, capable of specifically binding a secretagogue, such as ghrelin or a ghrelin-like compound. In another aspect of the present invention, a kit and method are provided for detecting a disorder in appetite regulation in an individual. The present invention also relates to use of the isolated binding members disclosed herein for the production of a pharmaceutical composition, for the treatment of an individual in need thereof. There is further provided herein a method for treatment of an individual in need thereof, comprising administering to said individual an effective amount of one or more of the pharmaceutical compositions of the present invention. The present invention further relates to isolated nucleic acid molecules encoding at least a part of the binding members disclosed herein and vectors comprising said nucleic acid molecules. Host cells comprising said nucleic acids are also disclosed, and the present invention further relates to a cell line engineered to express one or more of the binding members disclosed herein.
PCT/DK2005/000241 2004-04-07 2005-04-07 Uses of isolated binding members capable of binding specifically to secretagogues Ceased WO2005097831A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400574 2004-04-07
DKPA200400574 2004-04-07

Publications (2)

Publication Number Publication Date
WO2005097831A2 WO2005097831A2 (en) 2005-10-20
WO2005097831A3 true WO2005097831A3 (en) 2005-12-22

Family

ID=34964219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000241 Ceased WO2005097831A2 (en) 2004-04-07 2005-04-07 Uses of isolated binding members capable of binding specifically to secretagogues

Country Status (1)

Country Link
WO (1) WO2005097831A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045314A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
US20190382439A1 (en) * 2015-11-16 2019-12-19 Ubiprotein, Corp. Method for extending half-life of a protein
WO2021081326A1 (en) * 2019-10-25 2021-04-29 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017606A1 (en) * 1991-04-01 1992-10-15 Brigham And Women's Hospital Microassay system and neutrophil derived secretagogue
WO2001087335A2 (en) * 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
EP1197496A1 (en) * 1999-07-23 2002-04-17 Kenji Kangawa Novel peptides
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017606A1 (en) * 1991-04-01 1992-10-15 Brigham And Women's Hospital Microassay system and neutrophil derived secretagogue
EP1197496A1 (en) * 1999-07-23 2002-04-17 Kenji Kangawa Novel peptides
WO2001087335A2 (en) * 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANANTH S ET AL: "Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 9, 1 May 1999 (1999-05-01), pages 2210 - 2216, XP002117563, ISSN: 0008-5472 *
MACARTHUR C K ET AL: "A PEPTIDE SECRETED BY HUMAN ALVEOLAR MACROPHAGES RELEASES NEUTROPHIL GRANULE CONTENTS", JOURNAL OF IMMUNOLOGY, vol. 139, no. 10, 1987, pages 3456 - 3462, XP002352742, ISSN: 0022-1767 *
SPERBER KIRK ET AL: "In vivo detection of a novel macrophage-derived protein involved in the regulation of mucus-like glycoconjugate secretion", AMERICAN REVIEW OF RESPIRATORY DISEASE, vol. 146, no. 6, 1992, pages 1589 - 1597, XP009056431, ISSN: 0003-0805 *
STILES J D ET AL: "Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 56, no. 4, April 1997 (1997-04-01), pages 435 - 439, XP002117561, ISSN: 0022-3069 *

Also Published As

Publication number Publication date
WO2005097831A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
IL202795A0 (en) Amylin family peptides and methods for making and using them
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
EP2363460A3 (en) Acid fungal proteases
WO2008033413A3 (en) Albumin fusion proteins
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2007146038A3 (en) Albumin fusion proteins
WO2009068627A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
WO2007021494A3 (en) Albumin fusion proteins
NZ591415A (en) Haemophilus influenzae type B
WO2008040111A8 (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
EP2314615A3 (en) Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
WO2005097831A3 (en) Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A3 (en) Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
EP2447369A3 (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2008029138A3 (en) Peptides and methods
WO2006007565A8 (en) Cd40 variants skipping exon 5
WO2005089315A3 (en) Methods and compositions related to skcg-1, a tumor suppressor gene
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
WO2009028968A8 (en) Cell marker of melanocyte cell lineage and uses thereof
WO2010062756A3 (en) Preventing and treating sepsis
WO2004113519A3 (en) Alcohol dehydrogenase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases
WO2007079558A3 (en) Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment
WO2005003289A3 (en) Ap1 amine oxidase variants
WO2004056982A3 (en) Kinase sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase